Selecta reports additional Phase II data for gout combo

Selecta Biosciences Inc. (NASDAQ:SELB) reported additional data from an open-label, U.S. Phase II trial of lead candidate SEL-212 to treat chronic, severe gout. SEL-212 is a non-immunogenic therapy comprising pegsiticase (SEL-037), a pegylated uricase, co-administered with SVP-Rapamycin (SEL-110), a nanoparticle encapsulating the immunomodulator rapamycin.

Selecta said 14 of 19 evaluable patients who received three monthly doses of SEL-212 with 0.125 or 0.15 mg/kg SVP-Rapamycin and 0.2 or 0.4 mg/kg pegsiticase followed by two monthly doses of pegsiticase alone maintained control of serum uric acid levels, defined as <6 mg/dL, with concurrent mitigation of antidrug antibodies during the first three months. Additionally, the incidence of gout flares in SEL-212-treated patients was 37% at one month, 26% at two months and 5% at three months vs. 50% for patients who received pegsiticase alone for one month. Data were presented at the Pan American League of Associations for Rheumatology meeting in Buenos Aires...